- Home
- WHLR vs GLTO Comparison
WHLR vs GLTO Comparison
Compare WHLR & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHLR | GLTO |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 54.5M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WHLR | GLTO |
|---|---|---|
| Price | $1.80 | $28.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 5.4M | 113.5K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 61.36 | N/A |
| Revenue | ★ $101,834,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.69 | $2.01 |
| 52 Week High | $6,719.86 | $38.33 |
Technical Indicators
Market Signals| Indicator | WHLR | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 50.18 |
| Support Level | $1.69 | $24.53 |
| Resistance Level | $6.85 | $38.33 |
| Average True Range (ATR) | 0.36 | 4.05 |
| MACD | -0.15 | -0.54 |
| Stochastic Oscillator | 3.89 | 7.03 |
Price Performance
Historical ComparisonAbout WHLR Wheeler Real Estate Investment Trust Inc.
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.